HM 15136

Drug Profile

HM 15136

Alternative Names: LAPSGlucagon Analog; HM15136

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperinsulinaemia

Most Recent Events

  • 22 May 2018 Phase-I clinical trials in Hyperinsulinaemia in South Korea (IV) (Hanmi pipeline, May 2018)
  • 22 May 2018 Phase-I clinical trials in Hyperinsulinaemia in South Korea (SC) (Hanmi pipeline, May 2018)
  • 11 Sep 2017 Pharmacodynamics and pharmacokinetics data from preclinical study in Hyperinsulinaemia presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top